Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
|Videos|February 5, 2014
Molecular Targets in Inflammatory Breast Cancer
Author(s)Komal L. Jhaveri, MD
Komal L. Jhaveri, MD, Assistant Professor, Department of Medicine, NYU Langone Medical Center, discusses molecular targets in inflammatory breast cancer.
Advertisement
Komal L. Jhaveri, MD, Assistant Professor, Department of Medicine, NYU Langone Medical Center, discusses molecular targets in inflammatory breast cancer (IBC).
Clinical Pearls:
- Inflammatory breast cancer (IBC) remains a very aggressive cancer and women with the disease only live for a limited amount of time
- A lack of dedicated IBC trials is preventing researchers and physicians from determining novel pathways to target
- New discoveries about the biology of IBC has led researchers and physicians to understand pathways that are activated in the disease
- Studies have found that the PI3/AKT/mTOR pathway is activated in cell lines with IBC and xenograft models
- Tumor-associated macrophages cause activation of cytokines that leads to upregulation of the JAK-STAT pathway. Upregulation of this pathway leads to cell proliferation and survival
- Results of animal trials have shown overall survival benefit when both the PI3/AKT/mTOR pathway and the JAK-STAT pathway were inhibited
Advertisement
Related to this article
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.
Halfdan Sorbye, MD, PhD, discusses why accurately distinguishing NET G3 from NEC is critical, as the wrong first-line therapy can shorten survival.
Chrisann Kyi, MD, discusses the 79.3% response rate with sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and phase 3 plans.
Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.
Lauren Banks, MD, PhD, explains early findings from a pilot study of lifileucel in dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma, including treatment feasibility, safety, and response durability.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
Zocilurtatug Pelitecan Shows Activity in epNEC Across DLL3 Expression Levels
3
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
4
Dr Mohamed on Zocilurtatug Pelitecan for Refractory Extrapulmonary NEC
5